Are You Eligible for Weight Loss Injections on the NHS?

NHS weight loss injections are now available to more people than ever before, but access remains tightly controlled and strictly criteria-based. If you have been searching for clarity on weight loss injections NHS eligibility, this guide cuts through the confusion. You will learn which injections are currently available (Mounjaro, Wegovy, and Saxenda), the exact BMI and health thresholds that apply, how to access them through GP or specialist pathways, and what to do if you do not currently qualify.

Who qualifies for weight loss injections on the NHS?

Eligibility depends on which injection you are being assessed for, your BMI, and the number of weight-related health conditions you have. There is no single threshold that covers all three treatments. The criteria below reflect current NHS England guidance.

Mounjaro (tirzepatide) via your GP

This is the newest and most effective option, producing an average weight loss of around 20 to 22.5% of body weight in clinical trials. At present, you need:

• A BMI of 40 or above, AND
• At least four of the following: type 2 diabetes, high blood pressure, cardiovascular disease, high cholesterol, or obstructive sleep apnoea

If you are of South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean heritage, your BMI threshold is reduced by 2.5 points, reflecting the higher cardiovascular risk these groups carry at lower BMI levels.

The rollout is phased. From around June 2026, criteria are expected to broaden to include BMI 35 or above with four qualifying conditions. From March 2027, the threshold may shift again to BMI 40 or above with three conditions, though these later phases are subject to confirmation.

Wegovy (semaglutide) via specialist services

Wegovy requires a referral to a specialist weight management service rather than a GP prescription. You may be eligible if you have:

• A BMI of 35 or above (32.5 or above for the eligible ethnicities listed above) with at least one weight-related health condition, OR
• A BMI between 30 and 34.9 (27.5 to 32.4 for eligible ethnicities) and meet specific specialist referral criteria

Clinical trials showed average weight loss of around 13 to 21% of body weight with Wegovy. Prescriptions are currently limited to a maximum of two years, with a formal review at six months.

Saxenda (liraglutide) via specialist services

Saxenda is the oldest of the three and requires a daily injection rather than a weekly one. It produces more modest results, around 6 to 8% average weight loss. Eligibility requires:

• A BMI of 35 or above (32.5 or above for eligible ethnicities)
• Non-diabetic high blood sugar (pre-diabetes)
• High cardiovascular risk, such as high blood pressure or raised cholesterol

Saxenda is not suitable for people over 75 or those with significant liver or kidney disease.

How to access weight loss injections NHS services: the practical steps

This is where most guidance falls short. Knowing you might be eligible is one thing; knowing what to actually do is another.

For Mounjaro, book an appointment with your GP and ask whether your practice is currently prescribing it. Not all GP practices are participating yet, as the rollout is still in its early phase. If yours is, your healthcare team should proactively identify eligible patients. You do not need to self-refer; in fact, contacting your integrated care board (ICB) directly is often faster if your GP practice is not yet enrolled.

For Wegovy and Saxenda, ask your GP for a referral to your local specialist weight management service. Some areas permit self-referral. Waiting times vary considerably by region, with some ICBs reporting waits of six months or longer. To find your local service, search for your integrated care board online or use the NHS services directory at nhs.uk.

One cost consideration worth knowing: Mounjaro costs the NHS approximately £122 per month at its highest dose, which is a significant driver of the phased approach. If you are exempt from prescription charges, the injection is free to you. If not, the standard charge of £9.90 per item applies in England.

For a broader overview of prescription and non-prescription weight management options, the weight loss treatments hub at Star Pharmacy covers the main categories available in the UK.

What these injections do and why lifestyle changes are non-negotiable

All three injections are GLP-1 receptor agonists, meaning they mimic a naturally occurring gut hormone that signals fullness to the brain, slows stomach emptying, and reduces appetite. Mounjaro also activates a second receptor (GIP), which is thought to account for its stronger effect.

These are not appetite suppressants in the traditional sense. The mechanism is physiological. That said, they are not standalone treatments. NICE guidance and NHS policy both require a calorie-reduced diet and regular physical activity alongside the medication. The standard recommendation is around 600 fewer calories per day and at least 150 minutes of moderate exercise per week, with two sessions of strength training.

This matters because patients who do not maintain lifestyle changes regain weight relatively quickly once the injection stops, at roughly 0.8 kg per month compared with 0.1 kg per month for those who have embedded genuine behavioural changes. The injection is best understood as a window of opportunity to make habits stick, not a permanent fix.

People on GLP-1 injections who eat significantly less can also become deficient in key nutrients. Ensuring adequate protein, vitamin B12, vitamin D, and iron intake matters throughout treatment. Star Pharmacy’s vitamins & supplements section includes products relevant to people managing their nutritional intake during weight loss.

Side effects, safety, and who should not take them

Common side effects include nausea, diarrhoea, constipation, and stomach discomfort. These affect roughly one in ten people and usually improve as the body adjusts, typically within the first four to six weeks.

Rarer but more serious concerns include:

• Pancreatitis: affects approximately 1 in 100 people; seek urgent care if you develop severe upper abdominal pain
• Vision changes: reported with semaglutide (Wegovy); contact an eye specialist promptly if your vision changes
• Contraceptive pill absorption: tirzepatide and semaglutide reduce absorption of oral contraceptives; switch to a non-oral method (condom, implant, or IUD) during treatment
• Oral HRT: similar absorption issue; your doctor may recommend switching to a patch or gel

These injections are not suitable during pregnancy or breastfeeding. Inform your surgical team before any planned procedure, as these medications affect gastric emptying and anaesthesia safety.

Mounjaro, Wegovy, and Saxenda are all prescription-only medications. A consultation with a qualified healthcare professional is required before any of them can be prescribed.

What if you do not qualify yet?

Not meeting the current criteria does not mean there are no options. The NHS offers several other pathways.

Orlistat blocks fat absorption in the gut. It is available on NHS prescription for anyone with a BMI of 30 or above, or 28 or above with a weight-related health condition. It is less effective than the injections (around 30 to 40% of users lose 5% of body weight), but it is accessible without specialist referral.

Tier 1 and Tier 2 community weight management services include group programmes, dietitian referrals, and behavioural coaching. These are free through the NHS and available to people who do not yet meet the threshold for injections or surgery.

The NHS Digital Weight Management Programme provides remote support for people living with obesity who also have type 2 diabetes or hypertension. It is free and accessed via GP referral.

Bariatric surgery remains an option for people with a BMI of 40 or above, or 35 or above with a qualifying condition, where other treatments have not worked.

Conclusion

NHS weight loss injections represent a genuine shift in how obesity is treated in the UK. The eligibility criteria for weight loss injections NHS programmes are strict by design: the medication works best for people with the highest clinical need, and the phased rollout reflects real NHS capacity and budget constraints rather than arbitrary gatekeeping. If you qualify now, speak to your GP or contact your local ICB. If you do not qualify yet, Orlistat, community weight management services, and the NHS Digital Programme offer credible alternatives worth pursuing in the meantime.

Whichever pathway you are on, nutritional support during weight loss matters. You can explore prescription-grade weight management medicines and related support through Star Pharmacy’s weight loss management, where a qualified prescriber can assess your eligibility and guide next steps.

FAQs

Can I ask my GP to prescribe Mounjaro for weight loss?

Yes, but only if your GP practice is currently participating in the rollout and you meet the eligibility criteria: BMI 40 or above with at least four qualifying conditions. Your GP cannot prescribe outside these criteria during the current phase of the NHS programme.

Is Ozempic available on the NHS for weight loss?

No. Ozempic (semaglutide 1mg) is licensed for type 2 diabetes, not weight management. Wegovy (semaglutide 2.4mg) is the version approved for obesity on the NHS and requires a specialist referral.

Will I keep the weight off when I stop injections?

Research shows most people regain weight after stopping, at around 0.8 kg per month. People who maintain diet and exercise habits post-treatment tend to retain a meaningful portion of the weight loss. Planning the transition with your healthcare team before stopping is advisable.

Does my area offer these services?

Access varies by integrated care board. Contact your GP practice or search for your local ICB online. Some ICBs have not yet launched the Mounjaro GP pathway or have significant waiting lists for specialist services.